CircSCUBE3 Reduces the Anti-gastric Cancer Activity of Anti-PD-L1

Shan, Hu-Sheng; Zhang, Xiaobo; Zhang, Xiao; Wei, YingTian; Meng, LiangLiang; Li, Jing; Zhang, Zhong-Liang; Ma, Li; Xiao, Yueyong

doi:10.1007/s12033-023-00696-0

Cited by 4 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In GC, hsa_circ_0076092 is upregulated and associated with a poor prognosis, which can suppress immune escape by regulating PD-L1. More specifically, circSCUBE3 binds to miR-744-5p , which targets SLC7A5 [ 135 ].…”

Section: Micrornas: Bridging the Gap Between Gene Regulation Immune C...mentioning

confidence: 99%

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways

Zabeti Touchaei,

Vahidi

2024

Cancer Cell Int

View full text Add to dashboard Cite

Immunotherapy has revolutionized cancer treatment by harnessing the power of the immune system to eliminate tumors. Immune checkpoint inhibitors (ICIs) block negative regulatory signals that prevent T cells from attacking cancer cells. Two key ICIs target the PD-1/PD-L1 pathway, which includes programmed death-ligand 1 (PD-L1) and its receptor programmed death 1 (PD-1). Another ICI targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). While ICIs have demonstrated remarkable efficacy in various malignancies, only a subset of patients respond favorably. MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression, play a crucial role in modulating immune checkpoints, including PD-1/PD-L1 and CTLA-4. This review summarizes the latest advancements in immunotherapy, highlighting the therapeutic potential of targeting PD-1/PD-L1 and CTLA-4 immune checkpoints and the regulatory role of miRNAs in modulating these pathways. Consequently, understanding the complex interplay between miRNAs and immune checkpoints is essential for developing more effective and personalized immunotherapy strategies for cancer treatment. Graphical Abstract

show abstract

Section: Micrornas: Bridging the Gap Between Gene Regulation Immune C...mentioning

confidence: 99%

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways

Zabeti Touchaei,

Vahidi

2024

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

The role of α7nAchR and PD-L1 in neuroimmune regulation of keloid treatment

Luo,

Zheng,

Liu

et al. 2024

Cellular Signalling

View full text Add to dashboard Cite

Mechanism research of non‐coding RNA in immune checkpoint inhibitors therapy

Bian,

Shao,

et al. 2024

Cancer Science

View full text Add to dashboard Cite

Immune checkpoint inhibitor (ICI) therapies for tumors of different systems have attained significant achievements and have changed the current situation of tumor treatment due to their therapeutic characteristics of high specificity and low side effects. The immune checkpoint Programmed death 1/Programmed cell death‐Ligand 1 (PD‐1/PD‐L1) axis exerts a vital role in the immune escape of tumor cells. As a result, it has become a key target for tumor immunotherapy. Therefore, to perfect research into potential regulatory factors for the PD‐1/PD‐L1 axis, in order to understand and illustrate tumor ICI therapy mechanisms, is a significant goal. Moreover, ncRNA has been verified to regulate the PD‐1/PD‐L1 axis in the tumor immune microenvironment to regulate tumor genesis and development. ncRNAs can improve or decrease the efficacy of ICI therapy by modulating PD‐L1 expression. This review aimed to investigate the mechanisms of action of ncRNA in regulating the PD‐1/PD‐L1 axis in ICI therapy, to provide more efficient immunotherapy for tumors of different systems.

show abstract

CircSCUBE3 Reduces the Anti-gastric Cancer Activity of Anti-PD-L1

Cited by 4 publications

References 53 publications

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways

The role of α7nAchR and PD-L1 in neuroimmune regulation of keloid treatment

Mechanism research of non‐coding RNA in immune checkpoint inhibitors therapy

Contact Info

Product

Resources

About